Premature mortality for people with serious mental illness (SMI) is impacted by undertreatment of cardiovascular risk factors and metabolic effects of antipsychotic medications (Daumit et al., 2008; Nasrallah et al., 2006) . National guidelines recommend screening and monitoring for metabolic risk factors in patients receiving antipsychotic medications (Association et al., 2004; Parks et al., 2008) . However, prior studies demonstrate rates of screening between 10-43% (Buckley et al., 2005; Morrato et al., 2010; Newcomer et al., 2004) .
Our study fielded a survey (available upon request) aimed to understand psychiatrists' beliefs about their roles in, and the barriers to, the screening, monitoring and treatment of metabolic risk factors in patients receiving antipsychotic medications, and the characteristics of psychiatrists or their practices influencing differing attitudes. Items characterizing psychiatrists and their practices were adapted from prior national surveys (Arbuckle et al., 2008; Kreyenbuhl et al., 2007; Olfson et al., 2006) . Questions were developed based on previously hypothesized roles and barriers (Buckley et al., 2005; Morrato et al., 2010; Newcomer et al., 2004) and discussions with expert researchers. Five-point Likert scales were used to assess agreement with statements about psychiatrists' roles in the screening and treatment of metabolic risk factors, and whether 26 barriers were significant in their practices.
Between February 2009 and March 2010, a convenience sample of psychiatrists in two urban cities identified based on their affiliation with academic medical centers or local community mental health programs was contacted to anonymously complete a paper or online survey, without incentives. Inclusion criteria for the study were psychiatrists with outpatient practices. The study was approved by institutional review boards at both study locations and was in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
Likert scale responses were dichotomized into two groups, those responding "agree" or "strongly agree," and those responding otherwise. Ordinal logistic regressions were performed on responses to the first three key perceived roles (see Table 1 ) with the independent variables being provider and patient characteristics.
The response rate was 65% (91/139), and 92% (84/91) met inclusion criteria. The mean age for participants meeting inclusion criteria was 44.4 years old (SD=12.1), with 58% (48/83) of participants being male. The racial/ethnic distribution was 53% (42/80) Caucasian, 28% (22/80) Asian, 9% (7/80) African-American, 6% (5/80) Latino, and 5% (4/80) other.
Ratings for statements about the roles of psychiatrists in screening for and treating metabolic risks are shown in Ordinal logistic regression showed that psychiatrists graduating from residency before the 2004 ADA/APA guidelines (OR 4.27, 95% CI=1.62-11.2, p=0.003) and psychiatrists with fewer than half of their patients with diagnoses of schizophrenia or bipolar disorder (OR 3.75, 95% CI=1.52-9.25, p=0.004) were more likely to agree that monitoring is the role of psychiatrists only if patients did not have primary care providers. This may indicate an evolution over time in perceptions about screening and a need for targeted educational interventions for psychiatrists who have already completed training or with less contact with SMI populations. Psychiatrist or psychiatrists' practice characteristics were not associated with other perceived monitoring roles.
This study supports prior findings that psychiatrists recognize the importance of screening for metabolic risk in patients receiving antipsychotic medications (Newcomer et al., 2004) . Additionally, we found that psychiatrists believe their role includes conducting metabolic screening and providing certain interventions even if their patients have primary care physicians, but not prescribing oral medications for metabolic abnormalities. This gap between screening and treatment is concerning given that one of the top identified barriers was difficulty arranging medical follow-up, and may represent a target for interventions to provide psychiatrists with tools to initiate treatment of metabolic abnormalities.
This study has several limitations. This study used a convenience sample of psychiatrists in metropolitan centers. Differences between responders and non-responders are not known. The sample is not sufficiently large or diverse to assess the role of various work settings, institutional access to primary care, and other contextual factors on psychiatrist role perceptions regarding metabolic screening and monitoring.
This study provides a framework for future assessments of psychiatrists' perceived roles in and barriers to metabolic screening for people with SMI. Further surveys of other stakeholder groups (e.g., primary care providers, consumers) may help to elucidate the reasons for poor metabolic screening rates among persons with SMI and thereby help identify targets for intervention. Table 1 Psychiatrists' perceived roles in performing specific screening and monitoring tasks and in treatment for metabolic dysfunction.
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